Experimental combo targets Hard-to-Treat head and neck cancers

NCT ID NCT03381183

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two drugs — IRX-2 and durvalumab — in 19 people with advanced head and neck cancer that could not be cured by standard treatments. The goal was to see if the combination was safe and could boost the immune response inside tumors. The study focused on finding the right dose and checking for side effects, not on curing the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IRX-2 regimen (cyclophosphamide and IRX-2) and durvalumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that cannot be cured.
What could go wrong
This is a very early, small phase 1 trial with only 19 participants. The main goal is safety, not effectiveness. The treatment may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHARYNX SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.